Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 161-167

  Shyu, Yu Chiau ^a,b   Yuan, Shin Sheng ^c   Lee, Sheng Yu ^d,e   Yang, Chun Ju ^a,f   Yang, Kang Chung ^c,g   Lee, Tung Liang ^h   Wang, Liang Jen ⁱ  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

ADHD; Cohort study; Epidemiology; Psychosis; Stimulant

Indexed keywords

METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; BRIEF PSYCHOTIC DISORDER; CHILD; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DELUSIONAL DISORDER; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCHOOL CHILD; SURVIVAL RATE; TAIWAN; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; ONSET AGE; PROPORTIONAL HAZARDS MODEL; PSYCHOTIC DISORDERS; RISK; SURVIVAL ANALYSIS;

ADOLESCENT; AGE OF ONSET; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; SURVIVAL ANALYSIS; TAIWAN;

EID: 84942372828     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.08.033     Document Type: Article

References (42)

1. Andersen S.M., Randers A., Jensen C.M., Bisgaard C., Steinhausen H.C. Preceding diagnoses to young adult bipolar disorder and schizophrenia in a nationwide study. BMC Psychiatry 2013, 13:343.
2. Atzori P., Usala T., Carucci S., Danjou F., Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J. Child Adolesc. Psychopharmacol. 2009, 19(6):673-681.
3. Bakhshi K., Chance S.A. The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture. Neuroscience 2015, 303:82-102.
4. Biederman J., Monuteaux M.C., Mick E., Spencer T., Wilens T.E., Silva J.M., Snyder L.E., Faraone S.V. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol. Med. 2006, 36(2):167-179.
5. Brodsky K., Willcutt E.G., Davalos D.B., Ross R.G. Neuropsychological functioning in childhood-onset psychosis and attention-deficit/hyperactivity disorder. J. Child Psychol. Psychiatry 2014, 55(7):811-818.
6. Chen M.H., Li C.T., Lin W.C., Wei H.T., Chang W.H., Chen T.J., Pan T.L., Su T.P., Bai Y.M. A predisposition for allergies predicts subsequent hypertension, dyslipidemia, and diabetes mellitus among patients with schizophrenia or bipolar disorder: a nationwide longitudinal study. Schizophr. Res. 2014, 159(1):171-175.
7. Chen M.H., Su T.P., Chen Y.S., Hsu J.W., Huang K.L., Chang W.H., Chen T.J., Bai Y.M. Higher risk of developing mood disorders among adolescents with comorbidity of attention deficit hyperactivity disorder and disruptive behavior disorder: a nationwide prospective study. J. Psychiatr. Res. 2013, 47(8):1019-1023.
8. Cherland E., Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can. J. Psychiatry 1999, 44(8):811-813.
9. Corigliano V., De Carolis A., Trovini G., Dehning J., Di Pietro S., Curto M., Donato N., De Pisa E., Girardi P., Comparelli A. Neurocognition in schizophrenia: from prodrome to multi-episode illness. Psychiatry Res. 2014, 220(1-2):129-134.
10. Cuesta M.J., Peralta V. Psychopathological assessment of schizophrenia: relevance for classification. Curr. Psychiatry Rep. 2009, 11(4):324-331.
11. Dalsgaard S., Mortensen P.B., Frydenberg M., Maibing C.M., Nordentoft M., Thomsen P.H. Association between Attention-Deficit Hyperactivity Disorder in childhood and schizophrenia later in adulthood. Eur. Psychiatry 2014, 29(4):259-263.
12. Faraone S.V., Biederman J., Mennin D., Gershon J., Tsuang M.T. A prospective four-year follow-up study of children at risk for ADHD: psychiatric, neuropsychological, and psychosocial outcome. J. Am. Acad. Child Adolesc. Psychiatry 1996, 35(11):1449-1459.
13. FDA Report PID D040761 US Food and Drug Administration One year post-pediatric exclusivity postmarketing adverse event review: Adderall XR http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_05_02_AdderallSafetyReview.pdf.
14. Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81(3):515-526.
15. Hamshere M.L., Stergiakouli E., Langley K., Martin J., Holmans P., Kent L., Owen M.J., Gill M., Thapar A., O'Donovan M., Craddock N. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br. J. Psychiatry 2013, 203(2):107-111.
16. Hellgren L., Gillberg I.C., Bagenholm A., Gillberg C. Children with deficits in attention, motor control and perception (DAMP) almost grown up: psychiatric and personality disorders at age 16years. J. Child Psychol. Psychiatry 1994, 35(7):1255-1271.
17. Kim-Cohen J., Caspi A., Moffitt T.E., Harrington H., Milne B.J., Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch. Gen. Psychiatry 2003, 60(7):709-717.
18. Kraemer M., Uekermann J., Wiltfang J., Kis B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin. Neuropharmacol. 2010, 33(4):204-206.
19. Lakhan S.E., Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav. 2012, 2(5):661-677.
20. Larsson H., Ryden E., Boman M., Langstrom N., Lichtenstein P., Landen M. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br. J. Psychiatry 2013, 203(2):103-106.
21. Lindenmayer J.P., Nasrallah H., Pucci M., James S., Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr. Res. 2013, 147(2-3):241-252.
22. Maibing C.F., Pedersen C.B., Benros M.E., Mortensen P.B., Dalsgaard S., Nordentoft M. Risk of schizophrenia increases after all child and adolescent psychiatric disorders: a nationwide study. Schizophr. Bull. 2015, 41(4):963-970.
23. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry 1993, 50(7):565-576.
24. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am. J. Psychiatry 1998, 155(4):493-498.
25. Nussbaum N.L. ADHD and female specific concerns: a review of the literature and clinical implications. J. Atten. Disord. 2012, 16(2):87-100.
26. Owen M.J. Intellectual disability and major psychiatric disorders: a continuum of neurodevelopmental causality. Br. J. Psychiatry 2012, 200(4):268-269.
27. Owen M.J., O'Donovan M.C., Thapar A., Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br. J. Psychiatry 2011, 198(3):173-175.
28. Paksarian D., Eaton W.W., Mortensen P.B., Pedersen C.B. Childhood residential mobility, schizophrenia, and bipolar disorder: a population-based study in Denmark. Schizophr. Bull. 2015, 41(2):346-354.
29. Park J.H., Bang Y.R., Kim C.K. Sex and age differences in psychiatric disorders among children and adolescents: high-risk students study. Psychiatry Investig. 2014, 11(3):251-257.
30. Peralta V., de Jalon E.G., Campos M.S., Zandio M., Sanchez-Torres A., Cuesta M.J. The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. Schizophr. Res. 2011, 126(1-3):28-35.
31. Ross R.G. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am. J. Psychiatry 2006, 163(7):1149-1152.
32. Sagvolden T., Sergeant J.A. Attention deficit/hyperactivity disorder-from brain dysfunctions to behaviour. Behav. Brain Res. 1998, 94(1):1-10.
33. Spencer T.J., Biederman J., Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J. Pediatr. Psychol. 2007, 32(6):631-642.
34. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol. Drug Saf. 2007, 16(3):241-249.
35. Tarbox S.I., Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., Heinssen R., McGlashan T.H., Woods S.W. Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev. Psychopathol. 2013, 25(4 Pt 1):1171-1186.
36. Taurines R., Schmitt J., Renner T., Conner A.C., Warnke A., Romanos M. Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten. Defic. Hyperact. Disord. 2010, 2(4):267-289.
37. Tebartz van Elst L., Pick M., Biscaldi M., Fangmeier T., Riedel A. High-functioning autism spectrum disorder as a basic disorder in adult psychiatry and psychotherapy: psychopathological presentation, clinical relevance and therapeutic concepts. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(Suppl. 2):S189-S196.
38. van der Werf M., Hanssen M., Kohler S., Verkaaik M., Verhey F.R., van Winkel R., van Os J., Allardyce J. Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia. Psychol. Med. 2014, 44(1):9-16.
39. Waltereit R., Banaschewski T., Meyer-Lindenberg A., Poustka L. Interaction of neurodevelopmental pathways and synaptic plasticity in mental retardation, autism spectrum disorder and schizophrenia: implications for psychiatry. World J. Biol. Psychiatry 2014, 15(7):507-516.
40. Watkins C.C., Andrews S.R. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res. 2015 Jul 30, pii: S0920-9964(15)00362-X [Epub ahead of print]. 10.1016/j.schres.2015.07.018.
41. Weiss G., Hechtman L., Milroy T., Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J. Am. Acad. Child Psychiatry 1985, 24(2):211-220.
42. Wilens T.E. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. 2008, 28(3 Suppl. 2):S46-S53.